OnKure Therapeutics Schedules Investor Call for Key Updates
OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company dedicated to advancing innovative precision medicines in oncology, has made a significant announcement regarding its upcoming investor call. This call will review preliminary data from the pivotal PIKture-01 trial focused on the company's lead candidate, OKI-219.
Details About the Upcoming Call
The investor call is scheduled for a new date of December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET). This adjustment comes as part of OnKure’s commitment to keeping investors informed. Participants joining the call can dial 877-407-0789 for U.S. access or 201-689-8562 for international joins, ensuring they reference conference ID 13750009. For those preferring a digital format, the call will also be available via a webcast on OnKure’s website, where a replay will be offered for at least 30 days following the presentation.
Preview of Presented Data
This investor call coincides with the company’s participation in the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS), where critical findings from the PIKture-01 study will be highlighted. OnKure has confirmed that selected posters will be showcased, including data on how OKI-219 operates as a mutant-selective inhibitor. This information aims to provide insights into the performance of this therapy on specific cancers.
Posters at the SABCS
A key poster titled "Preliminary Results from PIKture-01" will be presented by lead author Alexander Spira, MD, PhD, during Poster Session 3, held on December 12, 2024, from 12:30 PM to 2:00 PM CST. This presentation details the initial findings of OKI-219 as it tackles mutations linked to several solid tumors, including breast cancer.
Broader Goals of OnKure Therapeutics
OnKure continues to position itself as a leader specializing in treatments that address key oncogenic pathways. The focus remains not only on advancing OKI-219 but also on developing a pipeline of tumor-agnostic candidates that provide both efficacy and tolerability. By using a structure-based design platform, OnKure aims to address cancer types with unmet medical needs.
Engagement with the Research Community
OnKure's participation at major conferences like SABCS highlights its commitment to engagement with the research community. Sharing preliminary research findings promotes transparency and offers insights into the ongoing journey of drug development. Researchers and stakeholders are encouraged to learn more about OnKure's contributions to oncology through presentations and publications.
Financial and Operational Insights
While focusing on clinical advancements, OnKure is also maintaining a close eye on its financial health, ensuring the company can sustain its long-term vision. The forthcoming investor call will likely address these essential aspects, including strategies to allocate resources effectively and manage cash flow.
Frequently Asked Questions
What is the date of OnKure's investor call?
The investor call is scheduled for December 10, 2024, at 7:00 a.m. CT.
What will be discussed during the investor call?
The call will primarily focus on preliminary data from the PIKture-01 study regarding OKI-219.
How can I access the investor call?
You can dial 877-407-0789 (U.S.) or 201-689-8562 (international), and also access the call via a webcast on OnKure’s website.
What are the main objectives of the PIKture-01 trial?
The PIKture-01 trial aims to evaluate the efficacy of OKI-219 in treating advanced solid tumors with specific mutations.
How does OnKure approach drug development?
OnKure employs a structure-based drug design platform to develop precision medicines that target validated biological drivers of cancer.
